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Misfolding of protein molecules often leads to the formation of in-
soluble aggregates, and abnormal accumulation of such aggregates in
the affected tissues is a major pathological change observed in neuro-
degenerative diseases [1]. In pathologically observed inclusion bodies,
not only do full-length proteins constitute the insoluble aggregates,
but also those truncated fragments have been detected [2–5]. A cellu-
lar processing of proteins is thus considered to be mal-functioned,
which inhibits the proper folding of those proteins and thereby facil-
itates the aggregate formation. Such truncated proteins are rarely
formed in healthy controls; therefore, truncation-associated changes
in molecular properties of proteins would be an important factor in
the pathogenesis of neurodegenerative diseases.
Abnormal processing of TAR DNA binding protein-43 (TDP-43) has
been recently proposed to be associated with amyotrophic lateral scle-
rosis (ALS) and frontotemporal lobar degeneration (FTLD) [6,7]. TDP-
43 is a multi-domain protein: a Tudor-like N-terminal domain, two
RNA recognition motif domains (RRM1, RRM2) in the middle, and a
C-terminal Gly-rich region [8]. In physiological conditions, TDP-43functions as a DNA/RNA-binding protein that shuttles between nucle-
us and cytoplasm and thereby regulates an alternative splicing of
mRNA [9]. Under pathogenic conditions, in contrast, cytoplasmic inclu-
sions are observed that contain C-terminal fragments (CTFs) of abnor-
mally cleaved and hyper-phosphorylated TDP-43 [6,7]. Furthermore, it
should be noted that those CTFs are distinct in their electrophoretic
mobility among different clinicopathological sub-types of TDP-43 pro-
teinopathies [10,11]. Due to signiﬁcant effects of phosphorylation on
the electrophoretic mobility of proteins, it is still in debate whether
multiple sites in pathological TDP-43 are susceptible to proteolysis in
a disease-speciﬁc manner. We nonetheless suspect that multiplicity
of the potential cleavage sites in TDP-43 plays roles in diversifying
the molecular pathologies of TDP-43 proteinopathies.
Indeed, several cleavage sites have been suggested in an RRM2 do-
main (Val 193–Ile 257) [12–15]; Igaz et al. have successfully puriﬁed
TDP-43 fragments from inclusions in an FTLD brain and identiﬁed Arg
208 as one of pathological cleavage sites in TDP-43 [13]. In addition,
Asp 219 and Asp 247 have been proposed as alternative cleavage
sites by Nonaka et al. [14]. A proteolysis by caspase-3 at Asp 221 in
RRM2 also seems possible [12,15]. Based upon these results, multiple
sites in TDP-43 are susceptible to abnormal cleavage, which could
produce a variety of CTFs with different sizes. Any protease(s) re-
sponsible for cleaving TDP-43 have not been identiﬁed, or even it re-
mains unknown whether the proteolysis of TDP-43 is essential to the
disease mechanism. Despite this, several pathological fragments of
TDP-43 with distinct sizes are reminiscent of a proteolysis of amyloid
precursor protein (APP) in Alzheimer disease, in which diverse sets of
fragments, in particular Aβ 40 and Aβ 42, are generated [2]. Aβ42 is
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possesses distinct molecular properties; compared to Aβ 40, Aβ 42 ex-
hibits higher aggregation propensity [16] with reproduction of amy-
loid pathologies in model mice [17]. Accordingly, the site(s) to be
proteolyzed in a disease-associated protein will be a relevant factor
in a pathomechanism; indeed, ratio of Aβ 42 over Aβ 40, rather than
total amounts of Aβ, correlates with the load of pathological plaques
in the brain [18,19]. Given that multiple sites in TDP-43 are considered
to be susceptible to proteolysis in TDP-43 proteinopathies, it is impor-
tant to characterize the cleavage-site-dependent changes in molecular
properties of TDP-43 fragments.
In this study, we have examined the transient expression of TDP-
43 fragments in mouse neuroblastoma cells, Neuro2a. Based upon
molecular weights (20–25 kDa) of pathologically detected CTFs, par-
ticular attention has been paid on RRM2 as potential cleavage sites
of TDP-43. We have then shown that each of those fragments pos-
sesses distinct molecular properties including intracellular loca-
lization, RIPA-solubility, and phosphorylation and proposed a
mechanism in which multiplicity of the cleavage sites in TDP-43 re-
lates to the pathological diversity of TDP-43 proteinopathies.
2. Material and methods
2.1. DNA constructs, cell culture, and transfection
A vector, pIRESneo3 (Clontech), was used for the construction
of plasmids expressing human TDP-43 proteins tagged with a C-ter-
minal HA. Truncated products were ampliﬁed by PCR using full-
length human TDP-43 cDNA as a template. Mutations were intro-
duced by Quikchange mutagenesis (Stratagene), and all constructs
used in this study were conﬁrmed by DNA sequencing.
Mouse neuroblastoma Neuro2a cells were maintained in DMEM
(Wako) with 10% fatal bovine serum (FBS) in 5% (v/v) CO2 at 37 °C.
For immunostaining experiments, cells were seeded on a 4-well
chamber slide (Lab-Tek II Chamber Slide w/ cover CC2 glass slide,
Nalge Nunc international), while 6-well plates coated with polyethy-
leneimine were used for Western blotting analysis. Cells were trans-
fected with plasmids using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's instructions. After transfection for
4 h, culture media were replaced with DMEM with 1% FBS supple-
mented with 5 mM N6,2′-O-dibutyryl cAMP (dbcAMP, Nacalai Tes-
que) for differentiating Neuro2a cells. Following further incubation
for 36 h, cells were ﬁxed or lysed as mentioned below.
2.2. Immunocytochemistry
For immunostaining of HA-tagged proteins, cells were ﬁxed with
4% paraformaldehyde containing 0.12 M sucrose in PBS for 10 min,
permeabilized with 0.5% Triton X-100 in PBS for 5 min and blocked
with 0.1% bovine serum albumin (BSA) in PBS for 30 min. Cells were
then incubated with anti-HA-Fluorescein, High Afﬁnity (3F10)
(1:100 dilution, Roche) in PBS containing 0.1% BSA for an hour,
washed once with 0.1% Triton X-100 in PBS and twice with 0.1%
BSA in PBS. Nuclei were then counter-stained with Hoechst 33342.
Images were obtained by using a ﬂuorescence microscope (Olympus
IX70, LCPlan Fl ×40).
2.3. Cell lysis and electrophoresis
Cells were washed twice with PBS and harvested by a RIPA buffer
containing a protease inhibitor cocktail, Complete (EDTA-free, Roche
Diagnostics). In order to suppress the protein dephosphorylation dur-
ing cell lysis, 2 mM sodium ﬂuoride and 4 mM imidazole were also
added. After sonication, cell lysates were ultracentrifuged at
110,000×g for 30 min to separate into supernatant (a soluble fraction)
and pellets (an insoluble fraction). The pellets were re-dissolved in a50 mM Tris buffer (pH 8.0) containing 2% SDS with the same volume
with that of the corresponding supernatant. The protein concentration
in supernatant was determined by BCA assay using BSA as a standard.
A soluble fraction containing 10 μg of proteins and an insoluble
fraction with the same volume with the corresponding soluble frac-
tion were mixed with an SDS-PAGE sample buffer containing β-mer-
captoethanol and loaded on a 12.5% SDS-PAGE gel (PAGEL, ATTO)
after boiling for 5 min. Proteins were then electroblotted on a
0.2-μm PVDF membrane (Bio-Rad) and analyzed by Western blotting
using rabbit polyclonal anti-HA (Y-11, Santa Cruz Biotechnology,
1:1000), mouse anti-TDP-43 phospho-Ser409/410 antibody (Cosmo
Bio, 1:1000). Corresponding secondary antibodies that are conjugated
with HRP were used as follows; anti-rabbit (1:5000) and anti-mouse
(1:1000) antibodies. Blots were developed with the SuperSignal West
Dura chemiluminescent substrate (Pierce), and images were obtained
using LAS1000 (Fujiﬁlm).
3. Results and discussion
It has been shown that pathological TDP-43 fragments are intact in
the C-terminal region and exhibit electrophoretic mobility corre-
sponding to 20–25 kDa [20]. A simple calculation thus implies that
an abnormal cleavage occurs within or near RRM2 (Val 193–Ile 250)
of TDP-43 (shown in red, Fig. 1A). Indeed, Arg 208, Asp 219, and Asp
247 have been identiﬁed as potential cleavage sites under pathological
conditions (shown as a bold style in Fig. 1A) [13,14]. While it remains
unclear whether the other cleavage sites exist in TDP-43, we suspect
that molecular properties of CTF depend upon where its N-terminus
starts. To test this idea, we have prepared artiﬁcial CTFs of TDP-43
ranging from 17 to 26 kDa in the molecular weight (Fig. 1A); for spec-
iﬁcation of the truncation site, a CTF is denoted as TDP-43X, in which a
superscript, X, indicates a starting amino residue at its N-terminus.
Moreover, to facilitate immunodetection of TDP-43 proteins both in
cells and cell lysates, all TDP-43 variants in this study are fused with
an HA tag at the C-terminus and can thus be denoted as TDP-43X-HA.
3.1. Intracellular localization and inclusion formation of TDP-43 CTFs
As shown in Fig. 1B, full-length TDP-43 (TDP-43FL-HA) was local-
ized in the nucleus of a differentiated Neuro2a cell, which can be de-
scribed by the presence of a bipartite nuclear localization signal (NLS,
Lys 82–Lys 84 and Lys 95–Arg 98) in TDP-43 [21]. In contrast, TDP-
43Ala90-HA corresponding to the caspase-generated 35 kDa fragment
(Fig. 1A) remained mostly nuclear but was also detectable in the cy-
toplasm (Fig. 1C). This is explained by the lack of one cluster (Lys
82–Lys 84) of bipartite NLS in TDP-43Ala90-HA. When CTF started
from the amino residue near or within RRM2, such TDP-43 CTFs
(17–26 kDa) were distributed throughout the cell (Fig. 1D–H) due
to the complete absence of bipartite NLS. In fact, a dominant role of
the bipartite NLS in cellular localization of TDP-43 variants is consis-
tent with previous results published so far [13,21].
In addition to the changes in intracellular localization, truncation
of TDP-43 near or within RRM2 has been reported to produce inclu-
sions in the cell [13,14]. Notably, we found signiﬁcant differences in
propensity for inclusion formation among our artiﬁcial 17–26 kDa
fragments of TDP-43. As represented in Fig. 1D, which shows the cell
expressing TDP-43Cys173-HA, formation of intracellular inclusion bod-
ies was rare in TDP-43Met167, Cys173, Pro178, Ser183-HA. In contrast, as
represented in Fig. 1E (TDP-43Val193-HA) and F (TDP-43Arg208-HA), in-
clusions became evident in TDP-43Leu188, Val193, Cys198, Thr203, Arg208,
Gln213, Val220, Pro225-HA. Furthermore, a closer comparison among
those eight inclusion-forming fragments has shown that morphol-
ogies of inclusions fall into two categories; a relatively large single in-
clusion at the nucleus as shown in Fig. 1E (TDP-43Leu188, Val193, Cys198,
Thr203-HA) and multiple small dot-like inclusions at the cytoplasm as
shown in Fig. 1F (TDP-43Arg208, Gln213, Val220, Pro225-HA). When the
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Fig. 1. A series of TDP-43 CTFs exhibits distinct distribution in Neuro2a cells. (A) Truncation sites examined in this study are indicated as arrows in a primary sequence of TDP-43.
A number below each arrow represents a calculated molecular weight (kDa) of CTF. A region colored red corresponds to 2nd RRM domain, and potential caspase-3 sites are under-
lined. Also, residues indicated with a larger font size are cleavage sites reported under pathological conditions. Amino acid numbering is also indicated at both sides of the sequence.
(B–H) Neuro2a cells transfected with C-terminally HA-tagged TDP-43 variants indicated on top of each panel were immunostained with ﬂuorescein-conjugated anti-HA antibody
(green, upper panels) and counterstained with Hoechst 33342 for nuclear staining (blue, lower panels). Representative images taken by a ﬂuorescence microscope are shown.
(B) TDP-43FL-HA, (C) TDP-43Ala90-HA, (D) TDP-43Cys173-HA, (E) TDP-43Val193-HA, (F) TDP-43Arg208-HA, (G) TDP-43Ala235-HA, and (H) TDP-43Gly245-HA.
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43Ala230, Ala235, Ala240, Gly245-HA)were less potent in forming intracellu-
lar inclusions (e.g. Figs. 1G and H). Based upon these results, we sug-
gest that the cleavage site in TDP-43 is a relevant factor to regulate
formation of intracellular inclusions. Given that formation of patho-
logical inclusions often associates with decrease in the solubility of
proteins [22], we have next tested if our inclusion-forming TDP-43
CTFs become insoluble upon inclusion formation in cells.
3.2. TDP-43 CTFs are categorized into four distinct types based upon its
molecular properties
Cells expressing TDP-43 CTFs were ﬁrst lysed in a RIPA buffer; fol-
lowing ultracentrifugation, TDP-43 CTFs in supernatant (s) and pellets(p) were then probed by Western blotting using an anti-HA antibody
(Fig. 2A). Intensities of the bands in supernatant and pellet fractions
were estimated from the blots, and a proportion of RIPA-insoluble
amounts to total amounts of TDP-43 CTFs was quantiﬁed, which we
call “insolubility” in this study. Based upon band patterns (Fig. 2A)
and insolubility (Fig. 2B), we categorized our eighteen TDP-43 vari-
ants into four types (type I, II, III, and IV).
3.2.1. Type I, RIPA-soluble CTFs
First, type I CTF exhibits approx. 25% of insolubility and includes
TDP-43FL, Ala90, Met167, Cys173, Pro178, Ser183-HA (Fig. 2B). While a single
band was mainly observed in type I CTFs, faint bands at 18 and
20 kDa were notable in TDP-43Met167, Cys173, Pro178, Ser183-HA (indicat-
ed by asterisks in Fig. 2A). Actually, these bands were observed also in
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Fig. 2. TDP-43 CTFs are categorized into four types. (A) Soluble supernatant (s) and insoluble pellets (p) of C-terminally HA-tagged TDP-43 variants expressed in Neuro2a cells were
analyzed by Western blot using an anti-HA antibody. Amino acid residues shown on top of the gel image represent N-terminal amino residues of CTFs. HA-immunopositive bands
due to internal initiation are indicated with asterisks (Fig. S1A). (B) Insolubility of TDP-43 CTFs was calculated from the band intensities of CTFs in supernatant and pellets shown in
(A). Three independent experiments were performed to estimate experimental errors.
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Gln213-HA, and considered to represent the products caused by inter-
nal initiation from Met 202 (a 20 kDa band) and Met 218 (a 18 kDa
band), which can be conﬁrmed by disappearance of these additional
bands with M202A and M218A mutations (Fig. S1A). Furthermore,
TDP-43FL-HA also showed an additional band with higher electropho-
retic mobility (~35 kDa), which has been attributed to the TDP-43
fragment internally initiated from Met 85 [23]. Cleavage producing
type I CTFs was found to occur at the site N-terminal to RRM2; there-
fore, CTFs with intact RRM2 seem to have less propensities for inclu-
sion formation with no increase in its insolubility.
3.2.2. Types II and III, RIPA-insoluble CTFs
When an artiﬁcial TDP-43 fragment starts from a residue within an
N-terminal region of RRM2 (i.e. TDP-43Leu188, Val193, Cys198, Thr203-HA),
insolubility of the resultant CTFs increases to approx. 60% (Fig. 2B),
and these CTFs are categorized as type II. In an insoluble fraction of
type II CTF, multiple bands were observed albeit blurry, while the cor-
responding RIPA-soluble CTF was detected as a clear single band
(Fig. 2A). Compared to these type II CTFs, the band multiplicity in
RIPA-insoluble fractions becomes more discrete in type III CTFs, in
which the truncation is performed in the middle of RRM2 (i.e. TDP-
43Arg208, Gln213, Val220, Pro225-HA, Fig. 2A). More speciﬁcally, while
the RIPA-soluble fractions of type III CTFs gave rise to clear single
bands, at least four discrete bands can be observed in the corres-
ponding RIPA-insoluble fractions. This is reminiscent of abnormalphosphorylation of the pathological TDP-43 CTFs [6,7]; indeed, as
shown later (Fig. 3), we have conﬁrmed that these multiple bands in
types II and III CTFs are caused by phosphorylation. It is, therefore, of
relevance to note that each of the type III CTFs exhibits distinct band
patterns in an insoluble fraction (Fig. 2A). In particular, in RIPA-insolu-
ble fractions, upper three out of total four bands exhibited distinct in-
tensities in each of type III CTFs; for example, relative intensities of
those three bands were much higher in TDP-43Gln213-HA than in
TDP-43Val220-HA (Fig. 2A). These results have thus implied that de-
grees of phosphorylation depend upon the truncation sites in TDP-43.
It is, furthermore, notable that type III CTFs are the most insoluble
among the TDP-43 fragments tested (~80% of insolubility). Type III
CTFs are found to correspond to the fragments that form multiple
dot-like inclusions in the cytoplasm (e.g. Fig. 1F), while type II CTF
forms a relatively large single inclusion at the nucleus (e.g. Fig. 1E).
Recently, intracellular proteolysis within an RRM2 of TDP-43, albeit
inefﬁcient, has been proposed to be a key event for producing inclu-
sions [24]. Based upon the results here, we further suggest that
where in an RRM2 is cleaved is an important factor to decide the for-
mation of either a large inclusion with moderate insolubility (type II)
or small dot-like inclusions with high insolubility (type III).
3.2.3. Type IV, RIPA-soluble but SDS-resistant oligomeric CTFs
Surprisingly, when we examined TDP-43 CTFs shorter than type III
(TDP-43Ala230, Ala235, Ala240-HA), these fragments categorized as type
IV were hardly detected at the predicted band positions (~18 kDa)
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Fig. 3. RIPA-insoluble type II and III CTFs of TDP-43 are phosphorylated. (A) Dephos-
phorylation of RIPA-insoluble TDP-43Val193-HA (type II, right panel) and TDP-
43Arg208-HA (type III, left panel) with alkaline phosphatase (AP) collapses multiple
HA-immunobands into a single band, which is consistent with the phosphorylation.
(B) RIPA-insoluble TDP-43Val193-HA (type II, right panel) and TDP-43Arg208-HA (type
III, left panel) are analyzed by Western blot using anti-HA antibody and anti-TDP-43
phospho-Ser409/410 antibody, which are aligned side-by-side. (C) Western blotting
analysis of soluble supernatant (s) and insoluble pellets (p) of TDP-43Arg208-HA with
mutations at indicated Ser residues. The blots were probed with an anti-HA antibody.
The bands indicated with an asterisk represent the TDP-43 species generated by inter-
nal initiation.
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soluble fraction with much retarded electrophoretic mobility, based
upon which the apparent molecular weight is estimated to be larger
than 250 kDa. Given that samples were loaded on an SDS-PAGE gel
after boiling in a sample buffer containing 0.1% SDS and 1% β-mercap-
toethanol, SDS-resistant and non-disulﬁde-bonding interactions in
type IV CTFs are responsible for formation of RIPA-soluble high-
molecular-weight oligomers. Puriﬁed His-tagged TDP-43Ala235 pre-
pared by its overexpression in E. coli was also detected as a
N250 kDa species from SDS-PAGE analysis, suggesting formation of
homo-oligomers (data not shown). Type IV CTFs did not form inclu-
sions in cells (e.g. Fig. 1G); therefore, those RIPA-soluble oligomers
are considered to diffuse throughout the cell. Very interestingly, fur-
thermore, a clear transition from type III to IV is observed when the
truncation site goes toward the C-terminus of TDP-43; in other
words, a RIPA-soluble oligomer was not detected in TDP-43Pro225,
Phe226, Arg227, Ala228, Phe229-HA but became evident in TDP-43Ala230-
HA (Fig. S1B). When the truncation occurred at the more C-terminal
site (TDP-43Gly245-HA), however, we could no longer observe the
RIPA-soluble oligomer; instead, such a CTF categorized as type III′ in
this study exhibits high insolubility (~80%) but no multiple bands in
the immunoblots (Fig. 2B) and also no visible inclusions in the cell
(Fig. 1H). While proteolysis within the folded structure of RRM2appears to be inefﬁcient [24], the RIPA-soluble oligomers could be
produced by truncation of TDP-43 in the region between Ala 230
and Gly 245, which covers the third β-strand and the second α-
helix in the βαββαβ motif of RRM2.
So far, in TDP-43 proteinopathies, less attention has been paid
upon a RIPA-soluble oligomer that can be detected in a high-
molecular-weight region of an SDS-PAGE gel. Furthermore, immuno-
blot analysis on the pathological TDP-43 has been often performed by
using a rabbit polyclonal anti-TDP-43 antibody from ProteinTech
Group [6,7]. Although this anti-TDP-43 antibody has been generated
against the N-terminal 260 amino acids of human TDP-43, effective
epitopes were found not to exist in the region between Arg 208 and
the C-terminus (Fig. S1C). Accordingly, the ProteinTech rabbit poly-
clonal TDP-43 antibody could not detect the RIPA-soluble oligomers
of our type IV CTFs, if any in pathological inclusions. Indeed, we con-
ﬁrmed that TDP-43Ala230, Ala235-HA (type IV CTFs) expressed in Neu-
ro2a cells were not probed with the ProteinTech polyclonal antibody
on the Western blots (data not shown). An antibody recognizing the
C-terminus of TDP-43 has been developed [20], wherein the Western
blotting analysis using that antibody was, however, not examined on
the RIPA-“soluble” fraction of affected tissues. Given that a key role of
soluble protein oligomers has been proposed on pathogenesis of sev-
eral other neurodegenerative diseases [25], in the future, it will be of
importance to clarify whether the RIPA-soluble oligomers with
N250 kDa are detected in patients with TDP-43 proteinopathies.
Based upon the quantitative comparison of insolubility, we pro-
pose that at least four distinct types of TDP-43 CTFs exist (Fig. 2).
When the truncation site is N-terminal to RRM2, the resultant CTFs
remain soluble (~25% insolubility) (type I). By contrast, truncation
of TDP-43 within RRM2 produces distinct CTFs with signiﬁcantly al-
tered properties: RIPA-insolubility of CTFs becomes high in type II
(~60%) and further increases in type III (~80%) but signiﬁcantly
drops in type IV (b25%). Type I, II and III CTFs are monomeric in the
presence of 0.1% SDS, but type IV CTF forms SDS-resistant oligomer.
Notably, immunobands of CTFs exhibit distinct multiplicity, which
was found only in the insoluble fraction (Fig. 2A). We have thus
next conﬁrmed that such multiplicity in immunobands represents
phosphorylation of CTFs and tested if the phosphorylation plays
roles in formation of aggregated CTFs with increased insolubility.
3.3. Aggregates and oligomers of TDP-43 CTFs are phosphorylated in the
cell
To conﬁrm that phosphorylation gives rise to multiplicity in
immunobands of type II and III insoluble CTFs (Fig. 2A), enzymatic de-
phosphorylation was examined. First, RIPA-insoluble fractions of cell
lysates were re-solubilized in a buffer containing 50 mM Tris/100 mM
NaCl/1 mM EDTA/2% SDS. After reduction of the SDS concentration by
a hundred-fold dilution in an alkaline phosphatase buffer, samples
were then incubated with alkaline phosphatase (E. coli C75, TAKARA)
at 65 °C for an hour. As shown in Fig. 3A, dephosphorylation of RIPA-
insoluble aggregates of TDP-43Val193-HA (type II CTF) and TDP-
43Arg208-HA (type III CTF) collapsed the multiple bands into a single
band, strongly suggesting the phosphorylation in insoluble aggre-
gates of type II and III CTFs.
In order to identify the phosphorylation sites in pathological TDP-43,
Hasegawa et al. [10] have generated multiple phospho-speciﬁc anti-
bodies that speciﬁcally recognize the potential phosphorylation sites
in TDP-43; among those, phospho-speciﬁc antibodies at phospho-Ser
379, 403, 404, 409 and 410 of TDP-43were found to intensely immuno-
stain the pathological inclusions in affected tissues. While it remains
obscure whether the other residues of TDP-43 are phosphorylated
under pathological conditions, Ser 409 and 410within TDP-43 in partic-
ular have been further conﬁrmed to be abnormally phosphorylated in
all familial and sporadic forms of TDP-43 proteinopathies [11]. In fact,
a phospho-S409/410-speciﬁc antibody detected the most upper band
1582 Y. Furukawa et al. / Biochimica et Biophysica Acta 1812 (2011) 1577–1583in a RIPA-insoluble aggregate of type II/III CTF (Fig. 3B) in our experi-
mental system, which shows phosphorylation at Ser 409 and 410. It is,
however, also notable that not all of those multiple bands are immuno-
reactive to the phospho-S409/410-speciﬁc antibody (Fig. 3B), suggest-
ing phosphorylation at the residues other than Ser 409 and 410.
Indeed, TDP-43Arg208-HA with S409/410A mutations still exhibited
multiple HA-positive immunobands in its RIPA-insoluble fraction
(Fig. 3C), which were again collapsed into a single band upon dephos-
phorylation (data not shown). It has been proposed that abnormal
phosphorylation also occurs at Ser 379, 403 and 404 in pathological
TDP-43 [10]; therefore, we further introduced quintuple mutations
(S379/403/404/409/410A) into TDP-43Arg208-HACTFs but still observed
multiple HA-immunoreactive bands in the RIPA-insoluble fraction
(Fig. 3C). Actually, a C-terminal region of TDP-43 is enriched in Ser;
twelve Ser residues (Ser 375, 377, 379, 387, 389, 393, 395, 403, 404,
407, 409, 410) exist in the region C-terminal to Tyr 374. When muta-
tions of all these twelve Ser residues to Ala (all S→A mutations) were
made in TDP-43Arg208-HA, a single HA-immunoband was detected in
the RIPA-insoluble fraction (Fig. 3C). These results have thus suggested
that multiple Ser residues in the C-terminal region of TDP-43 are sus-
ceptible to phosphorylation.
We initially suspected that phosphorylation on TDP-43 CTFs may
trigger the formation of RIPA-insoluble aggregates, because the phos-
phorylated forms of TDP-43 CTFs were detected only in a RIPA-insol-
uble fraction (Fig. 2A). This is, however, not the case; actually, the Ser
to Ala mutations in TDP-43Arg208-HA did not alter its insolubility
(Fig. 3C). In addition, insolubility of TDP-43Arg208-HA did not change
(or even slightly decreased) by introduction of phosphomimetic mu-
tations at Ser 379, 403, 404, 409, and 410 (Fig. S1D). Aggregate forma-
tion of TDP-43Arg208-HA in the cytoplasm (Fig. 1F) was not
appreciably affected by these phospho-deﬁcient and phospho-mi-
metic mutations (data not shown). Insolubility of TDP-43FL-HA in a
RIPA buffer was also unchanged in the presence of phosphomimetic
mutations at the C-terminal Ser residues (Fig. S1E); therefore, theseW
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Fig. 4. Limited effects of ALS mutations on insolubility and phosphorylation of TDP-43 CTFs
43FL; B, TDP-43Val193; C, TDP-43Arg208; D, TDP-43Ala235) with ALS-causing mutations indicate
into soluble supernatant (s) and insoluble pellets (p), which were then analyzed by Wester
intensities in those blots, insolubility of TDP-43 variants in a RIPA-buffer was calculated and
immunobands due to the internal initiation are indicated with asterisks.results suggest that phosphorylation does not increase the aggrega-
tion propensity of TDP-43 CTFs and is plausibly a “post-aggregation”
process. In other words, RIPA-insoluble but not soluble state of
CTFs might be a target for phosphorylation by as-yet-unidentiﬁed ki-
nases, and it can be considered in our experimental system that ec-
topic overexpression of CTFs in Neuro2a cells facilitates its
intracellular accumulation, RIPA-insolubilization, and then abnormal
phosphorylation.
3.4. Limited effects of ALS mutations on molecular properties of TDP-43
CTFs
More than thirty dominant mutations in a TDP-43 gene have been
identiﬁed as a cause of a familial form of ALS [26–29], while roles of
these mutations in the ALS pathomechanism remain obscure. To
test the effects of the pathogenic mutations on molecular properties
of our TDP-43 variants, three missense (A315T, M337V, A382T) and
one nonsense (Y374X) mutations have been introduced in TDP-
43FL-HA, TDP-43Val193-HA (type II CTF), TDP-43Arg208-HA (type III
CTF), and TDP-43Ala235-HA (type IV CTF). As performed above, full-
length TDP-43 and TDP-43 CTFs with ALS mutations were transiently
expressed in Neuro2a cells, lysed in a RIPA buffer and fractionated
into soluble supernatant and insoluble pellets. These fractions were
analyzed by Western blotting (Fig. 4A–D), and insolubility of TDP-
43 variants in a RIPA-buffer was estimated from the band intensities
(Fig. 4E). As a whole, we found no drastic changes in insolubility of
TDP-43 variants by ALS-causing mutations, although slight increase
in insolubility was observed in TDP-43FL-HA (A315T and Y374X)
and TDP-43Ala235-HA (M337V and Y374X) (Fig. 4E). Consistent with
our recent in vitro studies [30], these results suggest that ALS muta-
tions do not commonly increase the aggregation propensities of
TDP-43 variants.
Furthermore, patterns of multiple bands in the insoluble pellets of
TDP-43Val193-HA and TDP-43Arg208-HA were not affected by0
0
0
0
0
0
WT
A315T
M337V
A382T
Y374X
(E)
. Neuro2a cells were transfected with C-terminally HA-tagged TDP-43 variants (A, TDP-
d on top of the ﬁgure. Cell lysates in a RIPA-buffer were ultracentrifuged to fractionate
n blot using an anti-HA antibody. Based upon densitometric quantiﬁcation of the band
plotted in (E). Three independent experiments were performed to estimate errors. HA-
1583Y. Furukawa et al. / Biochimica et Biophysica Acta 1812 (2011) 1577–1583introduction of missense mutations, suggesting limited roles of ALS
mutations on phosphorylation (Fig. 4A–D). CTFs with Y374X muta-
tion did not exhibit additional bands due to phosphorylation, which
is, however, consistent with our ﬁndings that Ser residues susceptible
for phosphorylation are C-terminal to Tyr 374 (Fig. 3C). We hence
could not identify common effects of ALS mutations upon molecular
properties of full-length TDP-43 and three distinct types of CTFs, but
slight variations in insolubility and phosphorylation among mutant
TDP-43 CTFs may still have impact on the ALS pathomechanism.
3.5. Conclusions
In summary, depending upon where in TDP-43 is proteolyzed, the
resultant CTF was found to be categorized into four types, in each of
which the molecular properties are distinct such as the insolubility
in a RIPA buffer and the status of phosphorylation at the C-terminal
region. So far, pathological TDP-43 has been reported to exhibit di-
verse molecular properties that are distinct among clinicopathologi-
cal subtypes of TDP-43 proteinopathies. For example, an apparent
size of TDP-43 CTF in inclusions seems variable among subtypes of
TDP-43-positive FTLD cases [7,20], and differing phosphorylation pat-
tern in TDP-43 CTFs has also been proposed to occur in the cerebral
cortex of FTLD and ALS cases [10]. Even within sporadic ALS cases,
morphological distinction of TDP-43-positive inclusions has been
reported [31]. While it remains unclear which type(s) of CTFs deﬁned
here constitutes the pathological inclusions, cleavage-site-dependent
properties of TDP-43 CTFs would contribute to generate pathological
diversity in TDP-43 proteinopathies.
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